Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2001

View Archived Issues

Phase II trial of TH-9507 in type 2 diabetes cleared by FDA

NeuroSearch offers interim progress report

Hemosol given green light to proceed with Hemolink clinical program

FDA approval for Genesis IPG Spinal Cord Stimulator system

Rebetol receives Japanese approval for use in combination with Intron A for hepatitis C

AASLD news: Gilead's adefovir dipivoxil improves liver function and reduces viral load in HBV

Design and biological activity of new camptothecin glycoconjugates described by Bayer

Accelerated progress marks Q3 at Xenova

Primary endpoint of large tifacogin trial in sepsis patients not met according to Chiron

Specific activation of amygdala neurons and brain penetration demonstrated for secretin

Interim report shows British Biotech continues to make good progress

Preclinical data support use of dexanabinol in neuroinflammatory disorders

Antimalarial prodrugs in development at Jacobus

Successful human somatic cell nuclear transfer and parthenogenesis

Second conference on neuroimmunophilins held during SFN meeting

Abbott continues to pursue highly selective ETA receptor antagonists

Introduction of SynX's diagnostic aid for Alzheimer's disease

M-55113: an anticoagulant factor Xa inhibitor designed at Mochida

New product significantly reduces the risk of AMD

Abbott's acquisition of Vysis clears antitrust review

Specific inhibition of MMP-2 binding to alphavbeta3 integrin for inhibiting angiogenesis

Antitumor sulfonamide derivatives reported in recent patent by Sankyo

Protein tyrosine kinase inhibitors from AHP exert antitumor activity in vitro

Lactam inhibitors of Abeta peptide and their use in Alzheimer's disease and related disorders

ADIR prepares inhibitors of monoamine reuptake for CNS disorders

New gastric antisecretory agents designed by Byk Gulden

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...